These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effects of mixing glargine and short-acting insulin analogs on glucose control. Kaplan W; Rodriguez LM; Smith OE; Haymond MW; Heptulla RA Diabetes Care; 2004 Nov; 27(11):2739-40. PubMed ID: 15505016 [No Abstract] [Full Text] [Related]
23. For parents. Type 1 diabetes research. Balancing hope with realism. Dinsmoor RS Diabetes Self Manag; 2003; 20(2):87-8, 91-2, 95, 99-102. PubMed ID: 12715738 [No Abstract] [Full Text] [Related]
24. A case of lipoatrophy with Lispro insulin without insulin pump therapy. Arranz A; Andia V; López-Guzmán A Diabetes Care; 2004 Feb; 27(2):625-6. PubMed ID: 14747261 [No Abstract] [Full Text] [Related]
25. Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised? Bell DS Drugs; 2007; 67(13):1813-27. PubMed ID: 17722952 [TBL] [Abstract][Full Text] [Related]
26. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients. Ahmed AB; Home PD Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967 [TBL] [Abstract][Full Text] [Related]
27. Pramlintide: FDA wants more. Diabetes Obes Metab; 2001 Oct; 3(5):386. PubMed ID: 11710342 [No Abstract] [Full Text] [Related]
28. 2008 resource guide. Insulin. Along with human insulin analogs, recombinant DNA human insulins are the most widely used insulins in this country. Through genetic engineering, bacteria or yeast are transformed into little "factories" that produce synthetic human insulin. Diabetes Forecast; 2008 Jan; 61(1):RG11-4. PubMed ID: 18290288 [No Abstract] [Full Text] [Related]
29. Symlin up close. How people are benefiting from this injected drug. Spake A Diabetes Forecast; 2008 Mar; 61(3):50-1. PubMed ID: 18446978 [No Abstract] [Full Text] [Related]
31. New Insulins and New Aspects in Insulin Delivery. Woo VC Can J Diabetes; 2015 Aug; 39(4):335-43. PubMed ID: 26233724 [TBL] [Abstract][Full Text] [Related]
32. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Chapman TM; Noble S; Goa KL Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068 [TBL] [Abstract][Full Text] [Related]
33. Use of insulin glargine during pregnancy in a type 1 diabetic woman. Devlin JT; Hothersall L; Wilkis JL Diabetes Care; 2002 Jun; 25(6):1095-6. PubMed ID: 12032121 [No Abstract] [Full Text] [Related]
34. Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes. Rami B; Schober E Eur J Pediatr; 1997 Nov; 156(11):838-40. PubMed ID: 9392394 [TBL] [Abstract][Full Text] [Related]
35. Novel pharmacologic agents for type 2 diabetes. Uwaifo GI; Ratner RE Endocrinol Metab Clin North Am; 2005 Mar; 34(1):155-97. PubMed ID: 15752927 [TBL] [Abstract][Full Text] [Related]
36. Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes. Hedman CA; Orre-Pettersson AC; Lindström T; Arnqvist HJ Clin Endocrinol (Oxf); 2001 Jul; 55(1):107-12. PubMed ID: 11453959 [TBL] [Abstract][Full Text] [Related]
37. Insulin's sidekicks. Developing alternative medications for type 1 diabetes. Berg EG Diabetes Forecast; 2013 Sep; 66(9):38-40. PubMed ID: 24156144 [No Abstract] [Full Text] [Related]
38. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus. Burge MR; Waters DL; Holcombe JH; Schade DS J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507 [TBL] [Abstract][Full Text] [Related]